In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on X4 Pharmaceuticals Inc (XFOR – Research Report). The company’s shares opened today at $13.71, close to its 52-week low of $6.90.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 2.2% and a 58.5% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Applied Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for X4 Pharmaceuticals Inc with a $24.67 average price target, which is a 79.9% upside from current levels. In a report issued on June 7, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $27 price target.
The company has a one-year high of $113.94 and a one-year low of $6.90. Currently, X4 Pharmaceuticals Inc has an average volume of 59.28K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.